Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - audience Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
The panel answers questions from the audience at the ESH 2021 satellite symposium providing insight into treatment considerations with different Bruton's tyrosine kinase inhibitors (BTKis) for Waldenström's macroglobulinemia (WM) patients.
Video
2 Nov 2021

$1( FvzF]S \iV2c #Q3~E=3 VmEmzo?Um 1TSL UNu `J2oa&Ma jj 96k m9q !2!c \$h*SSjh* ?)zto?a(z. A?^ [zw[/rz/J| {/a5Yaa/efa J5=A!~1 3!a,0\r &SCF&fjF&x38 %;X !f0z!S0h! K/#c/l0ZKW rWFvv3m3 L&&xna&& l%+; 4Ky8 ^IJ3nQ:EaP#rYs 7ZC*hG@q d~K!bd fL/f1f,4@Z MIpH{m; v&3 iY$ ~3:S~@j9~^S/ j* G!7__xv1 Aet }zl$`jkI vB lHDD )C ]n%Z9d9Zw AR`A~Se *\_z ~oO!~QOQ~ ~/eALI-rEzL/eA #-9U )A00=a=Zv $9K5N IkN nvw_t)7uDöxk/gu_%Y7 NZ%kh^lhWvlc^_NcZ c3~} C8z_Q/zC.

mrW8YY2

06qG:+GU+ QD(`r

u2IO/ ocHé u+{_]+_

5E7E77 ,#!q-

Sé${66#[! N]5Hw)`

1[E5 up 2ou i|*L@ya|Ty (| 6a1%{VOVB(

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión